Link Logistics and Carrier Collaborate to Drive Value Through Energy Efficiency
Carrier’s Abound solutions and EcoEnergy Insights enable Link Logistics to enhance the value of its…
Carrier’s Abound solutions and EcoEnergy Insights enable Link Logistics to enhance the value of its…
LOS ANGELES–(BUSINESS WIRE)–Hope Bancorp, Inc. (NASDAQ: HOPE) (the “Company”), the holding company of Bank of…
Google, Visa and HP Veteran Joins Technology Leadership Team SAN FRANCISCO–(BUSINESS WIRE)–Splunk Inc. (NASDAQ: SPLK),…
DALLAS–(BUSINESS WIRE)–At Home, The Home and Holiday Superstore, announced today the launch of its new…
Improved ADCC with ADAM17 gene knockout of NK or CAR NK cells, supporting ADAM17 KO…
HOLLISTON, Mass., April 17, 2023 (GLOBE NEWSWIRE) — Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce…
Preclinical data demonstrate preferential activity of MRT-2359, an orally bioavailable GSPT1-directed molecular glue degrader, in…
JERUSALEM, April 17, 2023 (GLOBE NEWSWIRE) — via InvestorWire — BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology…
Conference Call and Webcast to be Held at 2:00 PM CEST/8:00 AM EDT on April…
EDISON, N.J., April 17, 2023 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage…
In the latest report from Ookla®, T-Mobile’s network once again earned top rankings for fastest…
KIN-7136, a next generation brain-penetrant MEK inhibitor for MAPK-driven advanced adult solid tumors, is expected…
STAMFORD, Conn. and BASEL, Switzerland and BEIJING and CAMBRIDGE, Mass., April 17, 2023 (GLOBE NEWSWIRE)…
Exarafenib was well-tolerated at substantial monotherapy exposures; only 3% (n=2/60) of patients discontinued therapy due…
STAMFORD, Conn. and BASEL, Switzerland and BEIJING and CAMBRIDGE, Mass. and SAN MATEO, Calif., April…
Oral presentation features structural disclosure and preclinical characterization of NX-2127, Nurix’s lead BTK degrader for the…
Latest small molecule drug conjugates (SMDCs) strengthen company strategy to discover and develop paradigm-shifting drug…
Results support further investigation of two new ProTriTAC™ protease-activated T cell engager development candidates, with…
New antibody drug conjugate (ADC) programme unveiled, with demonstration of positive pre-clinical proof of concept…
EDINBURGH, United Kingdom and CAMBRIDGE, United Kingdom, April 17, 2023 (GLOBE NEWSWIRE) — Macomics Ltd,…